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Abstract 
In the last few years, the role of epithelial cell plasticity in cancer biology research has gained increasing attention. 
This concept refers to the ability of the epithelial cells to dynamically switch between different phenotypic cellular 
states. This programme is particularly relevant during the epithelial-to-mesenchymal transition (EMT) in cancer 
progression. During colonization, epithelial cells first activate the EMT programme to disseminate from a primary 
tumour to reach a distant tissue site. During this process, cells are transported into the circulation and are able to 
escape the immune system of the host. Then, a reverse process called mesenchymal-to-epithelial transition (MET) 
occurs on cells that settle in the distant organs. Although epithelial cell plasticity has an important impact on tumour 
biology, the clinical relevance of this concept remains to be recapitulated. In this review, we will update the current 
state of epithelial cell plasticity in cancer progression and its clinical implications for the design of therapeutic 
strategies, the acquisition of multidrug resistance, and future perspectives for the management of cancer patients. 
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Introduction 
The epithelial-to-mesenchymal transition (EMT) process was first described by developmental 
biologists as a highly conserved programme found in tissue remodelling during embryogenesis, 
histogenesis and organ morphogenesis. During this process, the embryonic epithelial cells suffer a 
phenotypic conversion to give rise to individual and migratory cells. During EMT, epithelial cell 
morphology is lost and the acquisition of motile characteristics results from the loss of apicobasal polarity 
and loss of cell–cell adhesion. The changes in cell polarity and cell–cell contacts are accompanied by 
actin cytoskeleton reorganization and by a disruption of cell adhesion to the extracellular matrix (ECM), 
allowing cells to penetrate into the ECM and migrate over distances, promoting metastasis. These newly 
formed mesenchymal phenotypes are characterized by an irregular, more extended and elongated shape 
and less strong cell–cell contacts compared to their epithelial counterparts, increasing their migratory 
ability [1], [2]. These phenotypic changes described were also observed in an early step during tumour 
progression and metastasis, elucidating the importance of the epithelial-to-mesenchymal transition in 
carcinomas [3]. Dr. Elizabeth Hay, who first described the EMT, illustrated the essential differences 
between movement in embryogenesis and tumorigenesis, defining the distinct EMT mechanism [4], [5], 
[6]. 
 
Given that most tumours are carcinomas, which arise from epithelial cells, EMT in cancer has been 
established as a crucial event. One of the hallmarks of EMT is the loss of expression of a key epithelial 
cell–cell adhesion molecule, E-cadherin. E-cadherin is the prototype and best characterized member of 
adherens junctions in epithelial cells and is considered to be a potent tumour suppressor. Although the 
decreased expression of E-cadherin is a characteristic of the EMT, this process is also characterized by 
the downregulation of other epithelial specification genes, such as components of tight junctions (ZO1), 
desmosomes (Desmoplakin), cytokeratins, and laminin. The loss of epithelial markers is accompanied by 
the induction of mesenchymal markers, such as N-Cadherin, cadherin-11 or vimentin, by the nuclear 
accumulation of β-catenin and by the reorganization of the cytoskeleton [7], [8]. This process is triggered 
in response to several extracellular signals, such as epidermal growth factor (EGF), transforming growth 
factor beta (TGF-β), and hepatocyte growth factor (HGF). 
 
Given the crucial role of E-cadherin downregulation during EMT, different levels of E-cadherin 
regulation were extensively studied. It has been reported that at the transcriptional level, the activation of 
one or several transcription factors, referred to as repressors including the Snail/Slug family, Twist, 
ZEB1, and FOXC2, which are master molecular regulators of E-cadherin, also regulates the EMT. The 
loss of E-cadherin is driven by epigenetic control, by posttranscriptional regulators (such as microRNAs 
or RNA-binding proteins) [8], [9], [10], [11], or by posttranslational regulators (such as CK1 or Hakai) 
[12], [13], [14], [15], and these molecules regulate E-cadherin expression (Fig. 1). In addition to this level 
of regulation, the tumour microenvironment has also been shown to influence EMT by the modulation of 
cell–cell adhesion. For example, in the intestinal epithelium, EphB receptors are important regulators not 
only during embryogenesis but also during early stages of cancer progression. Indeed, EphB2 and EphB3 
control cell positioning and ordered migration in the intestinal epithelium [16], [17]. Multiple Eph 
receptors and/or their ephrin ligands (Eph-ephrin) are expressed in both cancer cells and the tumour 
microenvironment, influencing tumour properties by enabling aberrant cell–cell communication within 
and between tumour compartments. Eph-ephrin can promote the establishment of cadherin-based cell–
cell adhesion and epithelial phenotype [18], [19], [20]. 
  
 
 
 
Fig. 1. Epithelial plasticity. The ability of epithelial cells to dynamically switch between different phenotypic cellular states is 
depicted. During EMT, epithelial cells expressing epithelial markers undergo phenotypic changes to give rise to the mesenchymal 
phenotype. The induction of EMT can also induce stem cell properties (CSCs). EMT also occurs during the dissemination of cells 
from the primary tumour (DCTs). Circulating tumour cells (CTCs) detach from the primary tumour and travel in the bloodstream, 
spreading from the original tumour to other locations, leading to cancer metastasis. All of these cells exist in the peripheral blood of 
cancer patients, and the detection of CTCs can help to determine the process of metastasis. The reverse process, mesenchymal-to-
epithelial transition (MET), occurs during metastatic colonization once malignant cells extravasate and find their niche in distant 
organs. 
Since molecular biologists established the importance of E-cadherin as a hallmark of EMT, many 
studies reinforce that the loss of E-cadherin expression or function is associated with the transition from 
adenoma to carcinoma in clinical specimens. Pathologists also confirmed that loss of E-cadherin was 
associated with a lower differentiation grade and increased invasion and metastasis and is proposed as an 
indicator of poor prognosis [8], [21]. However, clinical evidence supporting the role of EMT in cancer 
progression is still open to discussion because the identification of cancer cells undergoing EMT in 
clinical specimens is very difficult to observe in primary tumours, making it reasonable for some 
pathologists to argue a concept that they have not clearly observed in their analysis of biopsies. The 
reverse process, known as mesenchymal-to-epithelial transition (MET), was also described to be 
necessary for metastatic colonization once malignant cells extravasate and find their niche in distant 
organs. Although this plasticity during EMT is considered to be the most striking manifestation of 
epithelial plasticity, the relative contribution of EMT to disease may be debatable because different 
degrees of epithelial plasticity have been observed. Cellular plasticity refers to the ability of cells to adopt 
an alternative cellular fate, differentiate into another cellular lineage (transdifferentiation), or 
dedifferentiate and revert to a less differentiated state of the same lineage. The induction of EMT can also 
induce stem cell properties [22]. Cancer stem cells (CSC) are a rare population within a tumour that has 
the ability to self-renew and seed a new tumour. CSCs can arise from either mutated normal tissue stem 
cells or from more differentiated cells that acquire stem cell properties, including self-renewal capacity 
and epithelial plasticity (EMT), due to genetic and epigenetic changes. CSCs can differentiate into all cell 
types of the heterogeneous tumour. In addition to cancer stem cells differentiating into transit-amplifying 
progenitor cells, the reverse process (dedifferentiation into CSCs) may also occur under certain conditions 
at various stages of cancer progression. Epithelial plasticity enables cancer cells to adapt to changes in the 
tumour (micro)environment. On the other hand, EMT also occurs during the dissemination of cells from 
the primary tumour. Circulating tumour cells (CTCs) are tumour cells that detach from the primary 
tumour and travel in the bloodstream, spreading from the original tumour to other locations and leading to 
cancer metastasis. These cells exist in the peripheral blood of cancer patients and the detection of CTCs 
can help to determine the process of metastasis. In contrast to other blood cells, the number of CTCs is 
very small in blood, which makes them difficult to detect. The advances in in vivo imaging techniques 
and in the characterization of EMT signatures in circulating tumour cells (CTCs) extracted from blood 
samples from patients supported that EMT occurs during dissemination from the primary tumour [23], 
[24], [25], [26]. Moreover, the reverse process, MET, was reported to be an important event in further 
metastasis when circulating tumour cells (CTCs) settle in distant organs and establish micrometastasis 
(Fig. 1). Therefore, epithelial plasticity can contribute to tumour heterogeneity, which describes the 
differences between tumours of the same type in different patients, and between cancer cells within a 
tumour. In addition, epithelial plasticity and heterogeneity in tumour biology also have an impact on the 
design of therapeutic strategies [27], given that one of the main risks in the appearance of tumour 
recurrence is associated with acquired multidrug resistance and the appearance of signs of EMT and 
stemness in the residual or relapsed tumour after chemotherapy. On the other hand, the prognostic value 
of the EMT-related genes or proteins was also evaluated (Table 1). Given the acquired clinical impact of 
epithelial plasticity in cancer progression, we will go into detail about the current state of this field, 
paying attention to the clinical implications to develop new clinical targets and to manage cancer patients. 
  
Table 1. Prognostic value of EMT related gene and protein expression in different tumours. 
Gene Expression Tumour Prognostic Hazard ratios Ref. 
      
Beta-
catenin 
Aberrant in tumour Gastric cancer Poor OS 1.85 (95% CI: 1.39–2.46) [28] 
Aberrant in tumour Oesophageal 
carcinoma 
Poor OS 1.71 (95% CI: 1.46–2.01) [29] 
Increased in nucleus of 
tumour cells 
CRC Poor DFS and OS 1.87 (95% CI: 1.28–2.71) and 1.55 
(95% CI: 1.12–2.14) 
[30] 
Reduced in tumour NSCLC Poor OS 1.91 (95% CI: 1.60–2.28) [31] 
Twist Aberrant, increased in 
tumour 
Several tumours Poor PFS/RFS/MFS/DFS/CFS 
and poor OS 
2.36 (95% CI: 1.76–3.17) and 2.07 
(95% CI: 1.63–2.63) 
[32] 
Snail Aberrant, increased in 
tumour 
Several tumours Poor PFS/RFS/MFS/DFS/CFS 
and poor OS 
1.54 (95% CI: 1.17–2.02) and 1.63 
(95% CI: 1.33–1.99) 
[32] 
E-
cadherin 
Reduced in tumour NSCLC Poor OS 1.19 (95% CI: 1.01–1.40) [33] 
Reduced in tumour NSCLC Poor DFS/PFS and poor OS 1.58 (95% CI: 1.21–2.05) and 1.59 
(95% CI: 1.39–1.80) 
[34] 
Reduced in tumour CRC Poor OS in Asian patients 2.86 (95% CI: 2.13–3.7) [35] 
Reduced in tumour Oesophageal 
cancer 
Poor OS 1.33 (95% CI: 1.16–1.52) [36] 
Reduced in tumour Gastric cancer Poor OS 1.62 (95% CI: 1.34–1.96) [37] 
Reduced in tumour Ovarian cancer Poor OS 2.10 (95% CI: 1.13–3.06) [38] 
Aberrant in tumour HNSCC Poor PFS and poor OS 2.628 (95% CI: 1.868–3.699) and 
2.533 (95% CI: 1.971–3.254) 
[39] 
Reduced in tumour PDAC Poor OS 1.80 (95% CI: 1.33–2.42) [40] 
Reduced or absent in 
tumour 
BIDC Increase risk of all-cause mortality 1.55 (95% CI: 1.08–2.23) [41] 
miR-200c Increased in blood Several tumours Poor PFS and poor OS 2.26 (95% CI: 1.66–3.08) and 3.07 
(95% CI: 1.58–5.96) 
[42] 
Decreased in tumour Several tumours Poor OS in stage I patients 0.41 (95% CI: 0.25–0.68) [42] 
      
 
NSCLC: non-small cell lung cancer; CRC: colorectal cancer; HNSCC: head and neck squamous cell carcinoma; PDAC: pancreatic 
ductal adenocarcinoma; BIDC: breast infiltrating ductal carcinoma; OS: overall survival; PFS: progression free survival; RFS: 
recurrence-free survival; MFS: metastasis-free survival; DFS: disease-free survival; CFS: cancer-free survival; CI: confidence 
interval; Ref.: references. 
Epithelial plasticity in cancer progression 
Metastasis is responsible for the majority of cancer-related deaths. However, the metastatic cascade is 
not an efficient process, as less than 0.01% of cells from a primary tumour enter the circulation and 
develop metastases [43]. In many solid tumours, carcinoma cells undergo the EMT process, allowing 
cells to disseminate and metastasize by the acquisition of invasive and stem cell-like characteristics of the 
epithelial cells [44]. A reverse process called mesenchymal-to-epithelial transition (MET) was proposed 
to endow the disseminated cells with the ability to establish micrometastases [45]. However, most of the 
studies in cancer biology that have reported the relevance of EMT in tumour progression were performed 
in vitro; therefore, the evidence supporting the epithelial and mesenchymal plasticity in vivo was highly 
questioned [46]. Moreover, the current technology used to determine the role of EMT during in vivo 
dissemination was mainly supported by the detection of the expression of epithelial markers of circulating 
tumour cells (CTCs), resulting in a questionable representation of metastases. Clinical observations from 
breast cancer showed the appearance of clinical metastases after years of the resection of a tumour that 
did not initially present clinical evidence of metastasis at the time of diagnosis; moreover, approximately 
4–5% of the clinical metastases develop without knowledge of the primary tumour [47]. These 
observations give rise to the idea that the dissemination of metastasis may occur even before the 
formation of a detectable primary tumour. This possibility has significant clinical and biological 
implications. 
 
Evidence supporting the epithelial and mesenchymal plasticity has been recently provided in vivo[48], 
[49], [50]. In two manuscripts, two additional regulators of epithelial plasticity were identified: 
transcription factor paired related homeobox 1 (PRRX1), whose expression correlated with invasive 
phenotypes, and TWIST1, an already established transcription factor regulator of EMT and metastasis 
[51], [52]. Both transcription factors PRRX1 and TWIST1 induce EMT to undergo further invasion, 
intravasation and extravasation. Moreover, the suppression of PRRX1 induced MET (in cells that 
underwent EMT), stem cell-like properties and proliferation. Indeed, it was demonstrated that PRRX1 
expression is associated with EMT and invasion, but its expression must be lost at later stages due to 
metastatic colonization. On the other hand, primary tumours expressing high levels of TWIST1 protein no 
longer expressed TWIST1 in most of the matched lymph node metastases. Using transgenic mice, it was 
demonstrated that suppression of Twist1 expression (which occurs as cells disseminate from the primary 
sites) was required for metastasis formation, but the induction of metastasis in these mice no longer 
expressed TWIST1 and an epithelial phenotype was observed, indicating that MET had taken place [48], 
[49]. Interestingly, the analyses of peripheral blood from these mice showed that Twist1 induction 
increased the number of circulating tumour cells (CTCs) that express TWIST1. Importantly, the 
suppression of Twist1 expression in these cells allowed for their proliferation in vivo, indicating that MET 
is crucial for metastatic outgrowth. Therefore, the induction of EMT by PRRX1 and/or TWIST1 
promotes invasion, intravasation and extravasation. Moreover, the downregulation of these EMT 
regulators is crucial for metastatic outgrowth. 
 
Pathologists have recognized that distant metastatic lesions mainly reproduce the histological pattern 
of the primary tumour; however, signs of the EMT process or markers associated with cells that have 
undergone EMT should not necessarily be present in metastases. Although the evidence of epithelial and 
mesenchymal plasticity has been shown in mice, cell plasticity was also studied in patients, thanks to in 
vivo imaging techniques and the analysis of CTCs taken from blood samples [23], [53]. Indeed, the 
presence of mesenchymal markers in circulating tumour cells and disseminated tumour cells predicts poor 
prognosis [54]. However, as previously mentioned, these results can be misinterpreted as the purification 
of CTCs based on the presence of epithelial markers in CTCs, such as the epithelial cell adhesion 
molecule EpcAM, leading to an underestimation of the amount of CTCs if they have already undergone a 
complete EMT [55]. 
 
Another important contribution underlying the involvement of EMT during in vivo tumour 
progression was reported by Rhim et al. [50]. In this paper, the authors proposed that pancreatic 
metastasis occurs earlier than previously anticipated. To clarify the early events of invasive behaviour, 
they developed a sensitive system that allowed them to tag and track pancreatic epithelial cells in a mouse 
model of pancreatic cancer to detect and isolate cells of pancreatic epithelial origin during tumour 
progression. This system allowed them not only to determine the in vivo EMT and dissemination kinetics 
but also to correlate the cell phenotype with the acquisition of invasive and tumour-initiating properties. 
They found that these tagged cells were invasive even before the malignancy could be detected by 
histological approaches. These mesenchymal cells expressed protein markers associated with EMT such 
as Slug, Snail and Zeb1. Moreover, the circulating pancreatic cells not only maintained the mesenchymal 
phenotype but also expressed cancer stem cell markers such as CD24 and CD44 [56], further supporting 
the previously reported association between EMT and stem cell properties [22]. Furthermore, it was 
demonstrated that inflammation enhances cancer progression in part by inducing EMT and dissemination. 
Indeed, they showed that the induction of pancreatitis increased the number of CTCs and EMT at the 
inflammatory foci; in contrast, the dissemination was abrogated by immunosuppressive treatment using 
dexamethasone. 
 
All of these investigations have an important clinical impact for future therapeutic strategies against 
metastasis. Inducing differentiation and targeting EMT alone might provoke the activation of the 
proliferation of disseminated cells, resulting in counterproductive therapy. Therefore, it is suggested that 
it may be useful to combine this therapy with standard chemotherapy to stop cycling cells. Indeed, 
clinical trials that compare neoadjuvant antimetastasis and cytotoxic therapies prior to surgery should be 
considered immediately for all cancer patients. 
Epithelial plasticity and cancer stem cells 
The EMT process has also been linked to the generation of epithelial cells that exhibit stem-cell 
properties. The concept of cancer stem cells (CSC) is still controversial, and it seems to be more 
appropriate to use the term “cancer stem cell paradigm” to refer to the existence of a rare population 
within a tumour that has the potential to self-renew and is responsible for the establishment, growth and 
maintenance of a tumour, having a high capacity for therapy resistance, angiogenesis and metastasis [22], 
[57]. One of the hypotheses regarding the origin of cancer stem cells is based on the transformation of a 
subpopulation of normal cells, which turn into CSC through their cellular plasticity. On the other hand, in 
specific tissues, it has been described that cancer stem cells express many features of the stem cell 
compartment, suggesting that tumorigenesis is initiated by the transformation of the stem cell 
compartment. For example, in normal crypts of the intestine, a graded expression of the EphB2 receptor 
in colorectal cancer has been reported that identifies the tumour cell population that exhibits intestinal 
stem cell-like or differentiated-like phenotypes [58]. These data support the idea that the local 
microenvironment may also contribute to the CSC phenotype and tumour heterogeneity. 
 
It was proposed that during the transition from the epithelial to the mesenchymal phenotype, EMT 
enhances the tumorigenesis or renewability of tumour cells; indeed, the CD44
+
/CD24
−
 subpopulation of 
normal and cancerous breast epithelial cells was suggested to have stem cell properties and express higher 
levels of EMT transcription factors than CD44
−
/CD24
+
 cells [22], [44]. Moreover, increased levels of 
several genes that activate the EMT process (such as TGF-β, Wnt, Notch, EGF, Oct4, Hedgehog, Nanog 
and TNF-α) were detected in cells that exhibit stem cell properties. External stimuli can induce breast 
CSC generation through EMT [59], which also underlines the importance of EMT in the generation of 
CSC, as it was shown that CTCs that undergo EMT frequently express CSC markers [60]. This evidence 
was suggested in other malignancies, such as colorectal, hepatocellular or pancreatic carcinoma [22], 
[61], [62], [63], [64]. The concept linking the EMT process and the generation of CSC opens up the 
possibility of developing therapeutic strategies designed to inhibit the EMT programme or to control 
MET in cancer cells. 
 
In addition, several transcription factors and posttranscriptional regulators were established to control 
the EMT process [2], [11]. Indeed, some have been linked to EMT and stem cell properties, such as Zeb1, 
which negatively regulates the expression of miR-200 family microRNA. miR-200 inhibits stemness 
through the suppression of polycomb protein Bmi-1 expression, which is necessary for efficient self-
renewing cell divisions [65], [66]. Several studies have shown that non-stem cells can dedifferentiate to 
stem-like cells spontaneously [67]. Later on, two transcription factors, Slug and Sox9, were identified to 
cooperate with the EMT to convert differentiated mammary epithelial cells into the mammary stem cell 
state [68]. Celià-Terrassa et al. reported the relationship between CSCs and EMT programmes in local 
invasiveness and distant metastasis. In this paper, they linked the properties of metastatic tumour-
initiating cells to an epithelial phenotype, suggesting that while enabling the invasiveness of tumour cells, 
EMT opposes the self-renewal gene programme that drives their local and metastatic growth [69]. 
Transcription factors that induce EMT may regulate proteins in self-renewal, but several signalling 
pathways involved in self-renewal can influence EMT. The Wnt-β-catenin pathway is involved in the 
induction of EMT and the generation and maintenance of CSC in several cancers, such as breast, colon, 
and liver carcinomas. Indeed, Wnt-β-catenin signalling has been proposed to be a major therapeutic target 
for the eradication of CSCs. Nuclear β-catenin is detected during EMT in the invading front of colorectal 
carcinoma. Moreover, Wnt signalling regulates the turnover and activity of the transcription factor Snail 
in breast cancer and in normal hepatocyte regeneration, providing a link between the regulation of EMT 
and Wnt signalling programmes through Snail. Through its action in repressing E-Cadherin expression, 
Snail may contribute to the suppression of epithelial characteristics, reinforcing Wnt-β-catenin signalling 
[70], [71], [72], [73]. On the other hand, Twist has been linked to CSC properties unrelated to self-
renewal but related to the suppression of apoptosis by suppressing the pro-apoptotic effects of the Myc 
oncogene and by repressing p53-induced pro-apoptotic genes. Therefore, transcription factors such as 
Snail, Zeb1 or Twist were proposed to be good targets for the design of low-molecular-weight drugs for 
cancer therapy; however, the generation of drugs targeting these transcription factors has not been 
successful, as these proteins did not exhibit accessible catalytic domains for further studies by molecular 
docking. Another interesting perspective to approach this issue is by targeting the signalling pathways 
described to initiate EMT and maintain the cells in the stem cell state, such as TGF-β, EGF, FGFs, Wnt 
and Notch ligands [74]. The development of an important drug directed against these signalling pathways 
has been extensively studied. Therefore, it is plausible that the combination of different drugs targeting 
these signalling pathways will help cancer stem cells exit the stem cell state. 
Cellular plasticity of circulating tumour cells 
More than 90% of cancer deaths are a consequence of the progress of disseminated metastasis [75]. 
Because the detection of disseminating tumour cells (DTCs) is based on invasive procedures, in recent 
years, the potential utility of circulating tumour cells (CTCs) has emerged. CTCs are often detected in the 
peripheral blood of patients with metastasis, and their presence was shown to correlate with a worse 
clinical outcome in various cancer types [76]. For example, in metastatic breast cancer patients, CTCs 
isolated from blood were found to overexpress stem cell and epithelial-to-mesenchymal transition 
markers [77], [78], and a high expression level of Snail mRNA was detected in the blood of 
hepatocellular carcinoma patients with extra-metastasis [79]. Usually, the detection of CTCs is based on 
several procedures that distinguish them from the surrounding haematopoietic cells by several 
characteristics, including physical properties (size, density, electric charge, deformability) and biological 
properties (surface protein expression, viability and invasion capacity). Positive selection is usually 
carried out with antibodies against the epithelial cell adhesion molecule (EpCAM), and subsequent 
immunocytological detection of CTC is performed by using antibodies against cytokeratins (CK), the 
intermediate filaments of epithelial cells [80]. In the 1970s, the EpCAM molecule was identified as an 
epithelial cell adhesion molecule that was highly expressed in epithelial cancers and at lower levels in 
normal simple epithelia; even more importantly, EpCAM expression was absent in blood cells [81]. 
Among the current EpCAM-based technologies, the automated CellSearch® system (Veridex, Warren, 
NJ, USA) was approved by the Food and Drug Administration (FDA) for monitoring CTCs in metastatic 
breast, colon, and prostate cancers [82], [83]. Although this technology is being used for clinical 
applications, it has still not been shown to be able to drive therapeutic decisions, as the results obtained 
are based on the presence of EpCAM epithelial markers in CTCs, leading to the underestimation of the 
amount of CTCs if they have already undergone a complete EMT [55]. Indeed, an increasing body of 
evidence suggests that CTCs are highly heterogeneous [53], [84], [85], and several phenotypes can be 
detected: (1) epithelial tumour cells that express epithelial markers such as the EpCAM cell adhesion 
molecule; (2) epithelial-to-mesenchymal transition (EMT+) cells in which low levels of epithelial 
markers are expressed together with the up-regulation of mesenchymal markers; (3) CTCs with hybrid 
epithelial/mesenchymal tumour cells, as this phenotype was reported in patients with metastatic non-
small-cell lung cancer and metastatic breast cancer, and a higher incidence of CTCs that express EMT-
related proteins, such as vimentin and TWIST1, is often accompanied by the presence of stem cell 
markers; (4) irreversible mesenchymal tumour cells, a subpopulation of circulating tumour stem cells that 
has undergone EMT and become fixed in the mesenchymal lineage, therefore preventing it from returning 
to the epithelial phenotype; and (5) circulating tumour stem cells whose stem cell-like immunophenotype 
is based on hallmarks such as CD44
+
/CD24
−/low
[86]. Thus, circulating tumour stem cells and 
mesenchymal tumour cells are underestimated in cancer dissemination using this technology. Given that 
CSCs express transcription factors that induce EMT, such as TWIST, SNAIL, and SLUG [22], it is highly 
plausible that these cells have downregulated epithelial markers, such as EpCAM, and have upregulated 
numerous mesenchymal markers. Therefore, CTCs including epithelial tumour cells (using markers such 
as EpCAM, EGFR, HER2, or Muc1), mesenchymal tumour cells (using mesenchymal markers such as N-
cadherin, O-cadherin, vimentin, and fibronectin) and circulating tumour stem cells (using CD26, CD44, 
CD133, CXCR4 markers) may co-exist in the peripheral blood. Although CellSearch is presently the only 
technology approved by the FDA, several trials have been reported concerning the evaluation of CTCs 
with mesenchymal features, for example, using the mRNA expression of EMT transcription factors. 
These systems overcome the discussed limitation of EpCAM enrichment. Moreover, recent publications 
underline the prognostic value of CTC in disease progression and treatment resistance in several types of 
cancer [53], [87], [88], [89], [90], [91]. Given that EMT increases cell migration and invasion and 
facilitates metastasis in multiple carcinoma types and that MET has a role in secondary tumour growth 
[92], it has been proposed that the isolation of CTCs can be used. It would be more reliable to use a 
combination of physical methods and negative selection containing epithelial and non-epithelial 
phenotypes, including circulating tumour stem cells and mesenchymal tumour cells derived from EMT. 
However, the isolation of CTCs by the combination of these procedures does not necessarily select 
tumour-derived cells, as they can be contaminated by the presence of stromal cells or normal blood vessel 
cells, stem cells, or other types of cells found in lower quantities in the circulation [93]. 
 
On the other hand, CTCs are continuously exposed to a hostile environment in the blood. Indeed, it is 
probable that only a few CTCs shed in the bloodstream can survive. Indeed, CTCs can be eliminated in 
blood by natural killer (NK) cells, monocytes/macrophages, and neutrophils; therefore, CTCs need to 
develop a phenotype that can protect them from the immune system and make them resistant to cell-
mediated cell death. Given that CTCs express EMT and CSC markers and that both are involved in the 
decreased sensitivity to cytotoxic immune effectors, one could expect that several of those markers could 
be responsible for the resistance to cell-mediated cell death. Indeed, it was demonstrated that Snail-
induced EMT accelerates cancer metastasis not only through invasion but also through the induction of 
immunosuppression by inducing regulatory T cells. Moreover, although it was proven that Snail-
expressing melanoma cells do not respond to immunotherapy, the in vivo injection of Snail-specific 
siRNA expressing tumour cells significantly inhibited tumour growth and metastasis followed by 
systemic immune responses and an increased number of tumour-infiltrating lymphocytes [94], [95]. Still, 
little is known about how tumour cells escape from the immune system of the host; therefore, the 
identification of immune-escape mechanisms as potential targets to disrupt the metastatic cascade in 
cancer is an attractive future perspective that needs to be further investigated. 
Cancer drug resistance and EMT 
EMT not only is an essential process for cellular plasticity in normal tissues during organ 
development and in malignant phenotypes during the invasion and stemming of cancer cells but also has 
been linked to resistance to chemotherapy. At present, several ongoing trials and compounds are being 
tested to therapeutically target epithelial plasticity-related genes (Table 2); however, therapeutic 
resistance mediated by EMT has been observed in several types of cancers. Several publications support 
that EMT and the induction of EMT genes are part of an adaptive response to therapeutic drugs by the 
acquisition of mesenchymal features for gain-of-function and resistance to cell death. Several EMT 
transcription repressors of E-cadherin, such as Snail/Twist and Zeb1, were reported to induce drug 
resistance [96], [97]. Increased levels of Zeb-1 and Twist and reduced levels of E-cadherin and other 
epithelial markers correspond to resistance to several drugs, such as 5-fluorouracil, gemcitabine or 
cisplatin [98]. In several tumour types, such as pancreatic or colorectal tumours, EMT biomarkers such as 
E-cadherin or vimentin can be used as predictors of the treatment outcome of EGFR inhibitors [99]. In 
head and neck squamous cell carcinoma and non-small cell lung carcinoma, the increased protein 
expression of vimentin combined with the loss of E-cadherin, claudin 4, and claudin 7 was associated 
with genfitinib resistance [100]. Moreover, studies of drug sensitivity in various cancer cells show that 
following the EMT process, cells were resistant to radiation [101], paclitaxel [102] and cisplatin [103], 
[104]. Changes in EMT markers were also observed to be associated with insensitivity to 
chemoradiotherapy in non-small cell lung cancer [105]. Another described example in which EMT is 
linked to the acquisition of stem-like activities and insensitivity to the EGFR-targeted agent erlotinib was 
described for lung, pancreatic, and head and neck cancer cells [106], [107]. Moreover, EMT markers act 
as determinants of insensitivity to genfitinib, an EGFR-tyrosine kinase. In lung adenocarcinoma cells, the 
activation of Notch-1 signalling enhances EMT in genfitinib-acquired resistance [108]. In HER-positive 
metastatic breast carcinoma, a rate of inherent resistance to trastuzumab (Herceptin) over 70% was 
observed. Several studies supported the contribution of specific EMT transcription factors involved in this 
resistance to trastuzumab. Indeed, SLUG/SNAIL2-positive basal/HER2+ cell lines exhibited an inherent 
resistance to trastuzumab, and the stem-related CD44
+
/CD24
−/low
 mesenchymal phenotype was 
unresponsive to trastuzumab. When SLUG/SNAIL2-knockdown basal/HER2+ cell lines were injected 
into nude mice, a reduction in tumour growth and gain in sensitivity to trastuzumab were observed. These 
data support that these EMT transcription factors can enhance phenotypic plasticity, allowing 
basal/HER2+ breast cancer cells to dynamically respond to trastuzumab in stem cell-like states. The 
authors suggest that the determination of SLUG/SNAIL2 and a stem/CD44
+
 and CD24
−/low
 cell-associated 
protein may impact the therapeutic strategy for HER2+ breast carcinomas [109]. As tumorigenic 
CD44
+
/CD24
−/low
 cells may be resistant to chemotherapy and responsible for cancer relapse, it was 
demonstrated that the inhibition of EGFR/HER2 signalling through lapatinib treatment led to a decrease 
in the percentage of tumorigenic cancer cells and in the self-renewal of HER2-positive cancers [110]. 
Another important example was observed in small cell lung cancer (SCLC) resistance to chemotherapy. 
Crizotinib is a drug that inhibits Met and Alk kinases, which act in patients with Alk-positive non-small 
cell lung cancer. Crizotinib is also effective in tumours with Met amplification. EMT can be induced by 
growth factors such as hepatocyte growth factor (HGF), the natural ligand of Met tyrosine kinase 
receptor. Selection of the correct patient population for specific treatment has become increasingly 
relevant for the impact of these targeted drugs in patients' outcomes [111], [112], [113]. It was 
demonstrated that by using preclinical models, the activation of the Met pathway induces the EMT 
phenotype in SCLC cells and generates a mesenchymal population that is more tumorigenic and 
chemoresistant to crizotnib than the parental cells. Met-specific inhibition via the modulation of these 
mesenchymal biomarkers subsequently increases chemosensitivity in SCLC models. Moreover, the 
mesenchymal features and Met phosphorylation are predictive of poor survival in patients with SCLC and 
are upregulated in chemoresistant or relapsed tumours. The authors proposed that Met-mediated EMT 
leads to chemoresistance, and the inhibition of MET is able to reverse this chemoresistance. Therefore, it 
was proposed that the selection of patients according to mesenchymal biomarkers in combination with 
Met expression is a good alternative for selecting patients with SCLC for clinical trials of Met inhibitors 
plus chemotherapy [114]. On the other hand, it was also reported that gold nanoparticles inhibited ovarian 
tumour growth and metastasis in mice by reverting EMT. Recently, it was suggested that the gold 
nanoparticles can prevent cisplatin-induced acquired chemoresistance and stemness in ovarian cancer 
cells and sensitize them to cisplatin [115]. Therefore, new therapeutic strategies are emerging to 
overcome the acquired drug resistance. 
Table 2. Selected ongoing clinical trials and compounds with targets potentially related to epithelial–mesenchymal plasticity. 
Compound Target Tumours Clinical trials* Phase 
     
Tivantinib (ARQ 197) c-Met Locally advanced or metastatic non-small cell lung 
cancer 
2010-022365-10 III 
Hepatocellular carcinoma 2012-003308-10 III 
Trametinib 
(GSK1120212) 
MEK1/2 BRAF mutant melanoma 2010-022838-85 
2012-001266-15 
2011-006088-23 
2011-006087-49 
III 
PD0325901 MEK1/2 Metastatic colorectal cancer, non-small cell lung cancer, 
pancreatic cancer 
2013-003299-10 II 
MSC2156119J c-Met Hepatocellular carcinoma 2013-002053-30 I/II 
PF-03446962 ALK Relapsed or refractory advanced or metastatic urothelial 
cancer 
2011-005983-12 II 
Galunisertib 
(LY2157299) 
TGFBR1 Advanced or metastatic unresectable pancreatic cancer 2011-000211-64 Ib/II 
Glioblastoma 2011-004418-40 II 
Hepatocellular carcinoma 2010-022338-10 II 
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Compound Target Tumours Clinical trials* Phase 
     
Linsitinib (OSI 906) IGF-IR, IR Ewing sarcoma 2012-000616-28 II 
Ovarian cancer 2009-010319-34 I/II 
Hepatocellular carcinoma 2010-018739-17 II 
Non-small cell lung cancer 2010-020916-12 II 
Nintedanib (BIBF1120) VEGFR1/2/3, 
FGFR1/2/3, and 
PDGFR-alpha/beta 
Colorectal cancer refractory to standard therapies 2012-000095-42 III 
Stage IIIB/IV or recurrent non-small cell lung cancer 
after failure of first line chemotherapy 
2007-004803-36 III 
MEHD7945A Dual EGFR/HER3 KRAS wild type metastatic colorectal cancer 2011-005547-27 II 
Squamous cell carcinoma of head and neck 2011-005539-22 II 
Binimetinib (MEK162) MEK1/2 Ovarian cancer 2013-000277-72 III 
Metastatic or unresectable (NRAS or BRAF mutant) 
melanoma 
2013-001176-38 
2013-001176-38 
2012-003593-51 
III 
Encorafenib (LGX818) BRAF BRAF mutant melanoma 2013-001176-38 III 
Rozrolimupab 
(Sym004) 
EGFR Anti-EGFR antibodies refractory metastatic colorectal 
cancer 
2013-003829-29 II 
Gedatolisib (PF-
05212384) 
PI3K/mTOR (PI3K-
alpha, PI3K-gamma, 
and mTOR) 
Metastatic colorectal cancer 2013-002096-18 
2013-002095-40 
II 
Endometrial cancer 2011-003062-32 II 
Neratinib (HKI-272) Dual EGFR/HER2 HER2 positive breast cancer 2012-004492-38 
2008-007345-31 
2008-005425-11 
2008-007803-10 
III 
Ganitumab (AMG 479) IGF-IR Metastatic pancreatic cancer 2010-020398-18 III 
Buparlisib (BKM120) Pan-PI3K (PI3K-
alpha, beta, gamma, 
and delta) 
Metastatic breast cancer 2011-005524-17 
2012-002571-34 
2011-005932-24 
III 
Encorafenib (LGX818) BRAF Unresectable or metastatic BRAF mutant melanoma 2013-001176-38 III 
BYL719 PI3K-alfa Hormone receptor-positive HER2-negative breast 
cancer 
2013-001862-41 II 
Dabrafenib 
(GSK2118436) 
BRAF BRAF mutant melanoma 2011-006087-49 
2012-001266-15 
2011-006088-23 
III 
Onartuzumab 
(MetMAb) 
c-MET Non-small cell lung cancer 2013-000868-29 
2011-002224-40 
III 
Gastro-oesophageal cancer 2012-001402-23 III 
Capmatinib (INC280) c-MET Locally advanced or metastatic BRAF mutant 
melanoma 
2012-004798-17 
2013-004552-38 
II 
EGF816 EGFR EGFR mutated non-small cell lung cancer 2014-000726-37 Ib/II 
LY2875358 c-MET Metastatic non-small cell lung cancer 2012-005476-33 
2012-005477-31 
II 
AMG 337 c-MET Gastric and oesophageal cancer 2013-001277-24 II 
Rilotumumab (AMG 
102) 
HGF Ovarian cancer 2011-001112-53 III 
Gastro-oesophageal cancer 2011-004923-11 III 
Ruxolitinib 
(INCB018424) 
JAK1/2 Advanced or metastatic pancreatic cancer 2014-000293-20 
2014-000294-39 
III 
Lucanix™ 
(Belagenpumatucel-L) 
TGF-β2 Non-small cell lung cancer 2007-005234-36 III 
Dacomitinib (PF-
00299804) 
Pan-Erbb (EGFR, 
HER2, and HER4) 
Non-small cell lung cancer 2012-004977-23 
2010-022656-22 
III 
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BGJ398 Pan-FGFR (FGFR1–
4) 
Recurrent resectable or unresectable glioblastoma 2013-002200-13 II 
Cholangiocarcinoma 2013-005085-19 II 
Locally advanced or metastatic BRAF mutant 
melanoma 
2012-004798-17 
2013-004552-38 
II 
PF 03084014 Gamma-secretase Advanced triple negative breast cancer 2014-002286-30 II 
MK-0752 Gamma-secretase Metastatic pancreatic cancer 2008-004829-42 II 
Catumaxomab 
(Removab™) 
Ep-CAM [monoclonal 
bispecific (also CD3-
specific) trifunctional 
(also with effector cell 
activation function) 
antibody] 
Peritoneal carcinomatosis from gastric or colorectal 
adenocarninomas 
2010-022810-26 II 
Gastro-oesophageal cancer with peritoneal 
carcinomatosis 
2010-024111-13 II 
Gastric adenocarcinoma after neoadjuvant 
chemotherapy and intended curative resection 
2006-002727-16 II 
Malignant ascites 2009-014076-22 II 
Cabozantinib (XL184) Multiple RTKs 
(VEGFR2, c-Met, 
RET, KIT, FLT1/3/4, 
Tie2, and AXL) 
VEGFR inhibitors refractory metastatic renal cell 
carcinoma 
2013-001010-14 III 
Sorafenib refractory hepatocellular carcinoma 2013-001001-91 III 
Previously treated symptomatic castration-resistant 
prostate cancer 
2012-001426-99 III 
Metastatic castration-resistant prostate cancer 2012-001834-33 III 
     
 
When possible, only phase III studies were indicated; otherwise, selected phase II studies were stated. The information was 
extracted from EU Clinical Trials Register (https://www.clinicaltrialsregister.eu). RTKs: Receptors Tyrosine Kinase. 
* EUdraCT Number. 
Conclusions 
In sum, it is clear that new therapeutic strategies need to be considered based on cellular plasticity. 
Strict action against cancer stem cells is unlikely to be a sufficient strategy given that stem cells can be 
generated from the remaining differentiated tumour cells. The combination of classical chemotherapy 
with anti-cancer stem cell drugs to attack non-stem and cancer stem cells within the tumour is a better 
option. Many efforts from the industry have focussed on the inhibition of metastasis by preventing the 
delamination of the primary tumour through the inhibition of EMT. Although this strategy is promising in 
specific types of cancer (as described in a mouse model of ovarian carcinoma) [116], the reported role of 
the epithelial plasticity during metastatic colonization opens up the possibility of favouring the formation 
of secondary tumours by the reversal of the mesenchymal phenotype to the epithelial phenotype through 
MET [48], [49] rather than preventing metastasis. This point is crucial in certain types of cancer, such as 
pancreatic or breast carcinomas, in which EMT occurs as a very early event in tumorigenesis and cancer 
cells have already disseminated before the tumour has been diagnosed [50], [117]. A promising strategy 
to determine the best therapeutic decision in every cancer patient is the generation of individualized 
mouse xenografts, named the “avatar mouse model.” The avatar mouse model carries cancer cells from 
individual human patients and allows personalized cancer treatment in real time [118], [119] by selecting 
the most effective treatment for the patient. Finally, an increasing body of evidence notes the relevance of 
the immune system in the regulation of cancer progression, facilitating survival in late stages of tumour 
progression. However, little is known about the mechanism involved in the tumour cells' escape from the 
immune system and the molecular markers involved in epithelial plasticity. New targets for therapeutic 
intervention to avoid immune system attack need to be elucidated. 
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